Ajay K. Kakkar

40.3k total citations · 21 hit papers
194 papers, 23.8k citations indexed

About

Ajay K. Kakkar is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Ajay K. Kakkar has authored 194 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Cardiology and Cardiovascular Medicine, 140 papers in Internal Medicine and 26 papers in Surgery. Recurrent topics in Ajay K. Kakkar's work include Venous Thromboembolism Diagnosis and Management (140 papers), Atrial Fibrillation Management and Outcomes (112 papers) and Cardiac Arrhythmias and Treatments (34 papers). Ajay K. Kakkar is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (140 papers), Atrial Fibrillation Management and Outcomes (112 papers) and Cardiac Arrhythmias and Treatments (34 papers). Ajay K. Kakkar collaborates with scholars based in United Kingdom, United States and Canada. Ajay K. Kakkar's co-authors include Samuel Z. Goldhaber, Mark N. Levine, Sylvia Haas, Sebastian Schellong, Frank Misselwitz, Sam Schulman, Henry Eriksson, Clive Kearon, Patrick Mismetti and Bengt I. Eriksson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Ajay K. Kakkar

189 papers receiving 23.1k citations

Hit Papers

Dabigatran versus Warfarin in the Treatment of Acute Veno... 2003 2026 2010 2018 2009 2003 2007 2017 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
    2009 1.9k citations Sam Schulman, Clive Kearon et al. profile →
  2. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
    2003 1.8k citations Agnes Lee, Mark N. Levine et al. profile →
  3. Venous thromboembolism (VTE) in Europe
    2007 1.1k citations Juan I. Arcelus, Ajay K. Kakkar et al. Thrombosis and Haemostasis profile →
  4. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
    2017 1.1k citations Peter Verhamme, Ajay K. Kakkar et al. profile →
  5. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
    2008 1.1k citations Samuel Z. Goldhaber, Ajay K. Kakkar et al. profile →
  6. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
    2008 1.0k citations Bengt I. Eriksson, Lars C. Borris et al. profile →
  7. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
    2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  8. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    2019 934 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  9. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
    2018 855 citations Annie Young, Andrea Marshall et al. Journal of Clinical Oncology profile →
  10. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    2008 807 citations Ajay K. Kakkar, Ola E. Dahl et al. profile →
  11. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  12. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
    2013 713 citations Sam Schulman, Clive Kearon et al. profile →
  13. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
    2013 688 citations Sam Schulman, Ajay K. Kakkar et al. Circulation profile →
  14. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  15. Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
    2004 519 citations Ajay K. Kakkar, Mark N. Levine et al. Journal of Clinical Oncology profile →
  16. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
    2017 492 citations Jeffrey I. Weitz, Henri Bounameaux et al. profile →
  17. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
    2011 401 citations Samuel Z. Goldhaber, Ajay K. Kakkar et al. profile →
  18. Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
    2012 382 citations Ajay K. Kakkar, Patrick Mismetti et al. profile →
  19. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
    2013 343 citations Ajay K. Kakkar, Iris Mueller et al. PLoS ONE profile →
  20. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
    2016 249 citations Henri Bounameaux, Alok A. Khorana et al. profile →
  21. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update
    2023 135 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ajay K. Kakkar United Kingdom 56 19.6k 16.8k 4.6k 4.3k 3.4k 194 23.8k
Paolo Prandoni Italy 67 21.2k 1.1× 13.5k 0.8× 8.3k 1.8× 5.5k 1.3× 5.4k 1.6× 299 25.1k
Menno V. Huisman Netherlands 76 20.0k 1.0× 15.5k 0.9× 5.8k 1.2× 3.5k 0.8× 3.2k 0.9× 469 29.6k
Walter Ageno Italy 67 13.7k 0.7× 11.4k 0.7× 4.0k 0.9× 1.9k 0.4× 3.6k 1.1× 557 20.5k
Henri Bounameaux Switzerland 58 17.4k 0.9× 11.4k 0.7× 5.6k 1.2× 3.3k 0.8× 3.2k 0.9× 222 20.9k
Gary E. Raskob United States 58 13.3k 0.7× 11.1k 0.7× 4.8k 1.0× 2.3k 0.5× 3.2k 1.0× 170 19.6k
Clive Kearon Canada 66 26.6k 1.4× 20.1k 1.2× 9.7k 2.1× 5.2k 1.2× 5.9k 1.7× 230 33.5k
William Geerts Canada 48 14.8k 0.8× 9.6k 0.6× 6.4k 1.4× 2.6k 0.6× 2.8k 0.8× 128 18.6k
Alok A. Khorana United States 69 13.2k 0.7× 8.1k 0.5× 3.7k 0.8× 5.0k 1.1× 3.0k 0.9× 360 20.8k
Giancarlo Agnelli Italy 63 11.6k 0.6× 9.3k 0.6× 3.5k 0.7× 2.4k 0.6× 1.9k 0.6× 335 16.4k
Manuel Monréal Spain 59 11.3k 0.6× 7.6k 0.5× 3.5k 0.7× 2.9k 0.7× 1.8k 0.5× 421 13.5k

Countries citing papers authored by Ajay K. Kakkar

Since Specialization
Citations

This map shows the geographic impact of Ajay K. Kakkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajay K. Kakkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajay K. Kakkar more than expected).

Fields of papers citing papers by Ajay K. Kakkar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajay K. Kakkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajay K. Kakkar. The network helps show where Ajay K. Kakkar may publish in the future.

Co-authorship network of co-authors of Ajay K. Kakkar

This figure shows the co-authorship network connecting the top 25 collaborators of Ajay K. Kakkar. A scholar is included among the top collaborators of Ajay K. Kakkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajay K. Kakkar. Ajay K. Kakkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prandoni, Paolo, Meg Fluharty, Sebastian Schellong, et al.. (2025). Sex differences in venous thromboembolism outcomes: findings from the GARFIELD-VTE registry. European Journal of Internal Medicine. 144. 106492–106492.
2.
Himmelreich, Jelle C L, Saverio Virdone, A. John Camm, et al.. (2024). Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF. Open Heart. 11(2). e002708–e002708.
3.
4.
Bassand, Jean‐Pierre, Saverio Virdone, A. John Camm, et al.. (2023). Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry. Diabetes Obesity and Metabolism. 25(10). 3040–3053. 1 indexed citations
5.
Fox, Keith A.A., Saverio Virdone, Karen S. Pieper, et al.. (2021). GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. European Heart Journal - Quality of Care and Clinical Outcomes. 8(2). 214–227. 27 indexed citations
6.
Gibbs, Harry, Ben Freedman, Mårten Rosenqvist, et al.. (2021). Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. The American Journal of Medicine. 134(7). 893–901.e11. 34 indexed citations
7.
Dalgaard, Frederik, Karen S. Pieper, Freek W.A. Verheugt, et al.. (2019). GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 9(11). e033283–e033283. 22 indexed citations
8.
Key, Nigel S., Alok A. Khorana, Nicole M. Kuderer, et al.. (2019). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 38(5). 496–520. 934 indexed citations breakdown →
9.
Young, Annie, Andrea Marshall, Oliver Chapman, et al.. (2018). Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology. 36(20). 2017–2023. 855 indexed citations breakdown →
10.
11.
Camm, A. John, Gabriele Accetta, Wael Al Mahmeed, et al.. (2017). Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7(3). e014579–e014579. 31 indexed citations
12.
Goldhaber, Samuel Z., Ajay K. Kakkar, Sebastian Schellong, et al.. (2015). Abstract 12422: Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER® and RE-COVER II™. Circulation. 1 indexed citations
13.
Lyman, Gary H., Kari Bohlke, Alok A. Khorana, et al.. (2015). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology. 33(6). 654–656. 968 indexed citations breakdown →
14.
15.
Singh, Manpreet, et al.. (2015). Image Encryption Scheme Based on Knight's Tour Problem. Procedia Computer Science. 70. 245–250. 10 indexed citations
16.
Schulman, Sam, Henry Eriksson, Samuel Z. Goldhaber, et al.. (2014). Abstract 18594: Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVER™ II. Circulation. 130. 4 indexed citations
17.
Kakkar, Ajay K., Iris Mueller, Jean‐Pierre Bassand, et al.. (2013). Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE. 8(5). e63479–e63479. 343 indexed citations breakdown →
18.
Eriksson, Bengt I., Kenneth A. Bauer, Lars C. Borris, et al.. (2007). Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thrombosis and Haemostasis. 97(6). 931–937. 56 indexed citations
19.
Zacharoulis, Dimitris & Ajay K. Kakkar. (2003). Venous thromboembolism in laparoscopic surgery. Current Opinion in Pulmonary Medicine. 9(5). 356–361. 19 indexed citations
20.
Kakkar, Ajay K., Mark N. Levine, Paolo Prandoni, et al.. (2002). What is the role for antithrombotics in cancer care?. Cancer Treatment Reviews. 28(3). 157–159. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Prandoni Breakdown of academic impact, for papers by Menno V. Huisman Breakdown of academic impact, for papers by Walter Ageno Breakdown of academic impact, for papers by Henri Bounameaux Breakdown of academic impact, for papers by Gary E. Raskob Breakdown of academic impact, for papers by Clive Kearon Breakdown of academic impact, for papers by William Geerts Breakdown of academic impact, for papers by Alok A. Khorana Breakdown of academic impact, for papers by Giancarlo Agnelli Breakdown of academic impact, for papers by Manuel Monréal
Rankless by CCL
2026